Skip to main content
. 2017 Jul 21;7:6171. doi: 10.1038/s41598-017-06275-z

Figure 1.

Figure 1

Reduction of inflammation, fibrosis and galectin-3 was found in the hearts of DMS-treated mice. (A) Experimental design of in vivo treatment. C57BL/6 mice infected with trypomastigotes (Colombian strain) were treated during the chronic phase of infection (6 months pos-infection) with DMS (200 µg/Kg/day; 3x week; i.p.). (B) Microphotographs of heart sections stained with hematoxylin and eosin or sirius red or anti-galectin-3 (1:50; red) and DAPI (blue). (C) Inflammatory cells were quantified in heart sections of naive mice, saline-treated chagasic mice, or DMS-treated chagasic mice and integrated by area. (D) The expression of CD45 was evaluated by real-time qRT-PCR using cDNA samples prepared from mRNA extracted from hearts of experimental groups. (E) Fibrotic area is represented by percentage of collagen deposition in heart sections. (F) Quantifications of galectin-3+ cells in heart sections were performed in ten random fields captured under 400x magnification, using the Image Pro Plus v.7.0 software. Bars represent means ± SEM of 10 mice/group. ***P < 0.001; **P < 0.01; *P < 0.05 compared to saline group; # P < 0.05 compared to naive group.